March 23, 2023
The National Council has drafted comments and is providing a shell for its members to use to send comments in response to the DEA’s recently published two Proposed Rules in the Federal Register regarding telemedicine prescribing of controlled substances, including buprenorphine, in anticipation of the end of the COVID-19 public health emergency (PHE).
See attached documents that you can make your own. In this case, the more comments the better, so please issue comments from your organization on your agency letterhead. The NYS Council will issue comments from everyone, but individual agencies count!
DEA Telemedicine Comment – Members 032323
DEA Buprenorphine Comment – Members 032323 (2)
Comments are due by 3/31/20023. You can submit your comments electronically using the www.regulations.gov website although I would not wait until the last few days to try and file using this site due to the volume of comments expected.